A meta-analysis indicates that GLP-1 receptor agonists may help decrease binge eating severity and emotional eating in individuals with obesity.
Key facts
- •The study analyzed 25 randomized controlled trials involving 8,069 participants.
- •Participants receiving GLP-1RAs showed moderate reductions in binge eating severity and emotional eating.
- •The trials included in the analysis ranged in duration from 6 weeks to 104 weeks.
- •Researchers identified a current gap in targeted research, as only three studies focused on patients with a formal binge eating disorder diagnosis.
- •Experts caution that rapid weight loss from these medications could potentially interfere with nutritional needs and eating disorder recovery goals.
A study published July 15 in eClinical Medicine suggests that GLP-1 receptor agonists (GLP-1RAs), typically used for type 2 diabetes and weight loss, may also reduce symptoms of binge eating disorder. Researchers conducted a meta-analysis of 25 randomized controlled trials to assess the impact of these medications on binge eating severity, loss of control, and emotional eating. The findings indicate moderate improvements in these behaviors among participants living with overweight or obesity.
By the numbers
Study Methodology and Findings
The systematic review analyzed data from 8,069 participants across 25 trials conducted between 2005 and April 2026. While the results showed consistent reductions in binge eating severity and loss-of-control episodes, the researchers noted that only three of the included studies specifically recruited individuals diagnosed with binge eating disorder. The analysis also found that GLP-1RAs were associated with increased cognitive or dietary restraint, which the authors noted could reflect either healthy self-regulation or, in some cases, a link to disordered eating behaviors.
Expert Perspectives on Treatment
Medical experts emphasize that these findings do not suggest GLP-1RAs should replace established treatments like cognitive behavioral therapy. Dr. Joel Jahraus of Monte Nido & Affiliates warned that non-specialists might prescribe these drugs without properly screening for eating disorders, potentially worsening binge behaviors. Experts advise that patients consult with an eating disorder specialist before considering these medications, as further long-term research is required to confirm their safety and effectiveness for this specific population.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Healthline.
